Retension Pharmaceuticals, Inc. (RTSN)
| Market Cap | 101.23M |
| Revenue (ttm) | n/a |
| Net Income | -14.24M |
| EPS | -17.67 |
| Shares Out | 8.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 91,492 |
| Open | 11.89 |
| Previous Close | 12.02 |
| Day's Range | 11.59 - 12.40 |
| 52-Week Range | 9.66 - 18.64 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 51.67 (+325.27%) |
| Est. Earnings | Nov 24, 2026 |
About RTSN
Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The Company operates as a single operating and reportable segment focused on the development of treatments for hypertension and cardiovascular disease. The company was incorporated in 2023 and is headquartered in... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for RTSN stock is "Strong Buy." The 12-month stock price target is $51.67, which is an increase of 325.27% from the latest price.
News
Retension Pharmaceuticals Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
RTN-001 is designed to reach central vasculature and lower blood pressure through a PDE5 mechanism outside the RAS axis. A 280-patient Phase II-B is underway, with data anticipated in H1 2027.
Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
FALLS CHURCH, Va., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing med...
Retension Pharmaceuticals initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Retension Pharmaceuticals (RTSN) with an Outperform rating and $50 price target Retension is a clinical-stage biopharmaceutical company focused on addressing the need...
Retension Pharmaceuticals initiated with a Buy at Guggenheim
Guggenheim analyst Seamus Fernandez initiated coverage of Retension Pharmaceuticals (RTSN) with a Buy rating and $55 price target The company offers a “differentiated approach” to the 30M U.S. patient...
Retension Pharmaceuticals Announces Pricing of Initial Public Offering
FALLS CHURCH, Va., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing med...
Biotech IPOs Charge Ahead as Tech Deals Stall
TRex Bio and Retension Pharmaceuticals are set to continue the industry's public debut rebound.
Retension Pharmaceuticals Registration statement: Registration filing
Retension Pharmaceuticals filed a registration statement on October 7, 2026, providing details about a securities offering with the SEC.
Retension Pharmaceuticals Registration statement: Registration filing
Retension Pharmaceuticals filed a registration statement on October 5, 2026, providing details about a securities offering with the SEC.
Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues
Drug developers Retension Pharmaceuticals and TRex Bio filed their paperwork for U.S. initial public offerings on Friday, reinforcing the biotech pipeline for the fall IPO window.
Hypertension drug developer Retension Pharmaceuticals files for a $58 million IPO
Retension Pharmaceuticals, a Phase 2b biotech developing an in-licensed treatment for hypertension, filed on Friday with the SEC to raise up to $58 million in an initial public offering.
Retension Pharmaceuticals IPO Registration Document (S-1)
Retension Pharmaceuticals has filed to go public with an IPO on the NASDAQ
Retension Pharmaceuticals Registration statement: Registration filing
Retension Pharmaceuticals filed a registration statement on September 18, 2026, providing details about a securities offering with the SEC.